ACRP blog
NOVEMBER 8, 2023
As several retail pharmacy chains proclaim a rosy outlook for ongoing efforts to expand their services into the clinical trials arena in the wake of the pandemic, traditional study site personnel and patients interviewed on the topic offered more mixed and nuanced concerns about the prospects for near-term success for such ventures.
ACRP blog
NOVEMBER 8, 2023
As several retail pharmacy chains proclaim a rosy outlook for ongoing efforts to expand their services into the clinical trials arena in the wake of the pandemic, traditional study site personnel and patients interviewed on the topic offered more mixed and nuanced concerns about the prospects for near-term success for such ventures.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
DECEMBER 28, 2020
Prior to that, Dr. Zhang was an equity research analyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine. .”
The Pharma Data
DECEMBER 31, 2020
Reimer replaces Charlotte Russel and will be responsible for Alligator’s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. Prior to that, Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector.
XTalks
JUNE 9, 2022
Still riding high on the approval of its dual-targeting GIP/GLP-1 injection Mounjaro (tirzepatide) for the treatment of type 2 diabetes, Eli Lilly continues to forage the path ahead with the drug, sharing new analyses that continues to build a strong case for it as a weight loss injection for obese patients. billion in sales by 2026.
Expert insights. Personalized for you.
59 
Let's personalize your content